Beyond Glioblas­toma — WPD Pharmaceuticals

WPD Phar­ma­ceu­ti­cals is a clin­i­cal-stage biotech­nol­o­gy com­pa­ny focused on devel­op­ing nov­el ther­a­pies for oncol­o­gy with spe­cial empha­sis on brain can­cer. WPD-401 is a nov­el and potent drug can­di­date com­ing from the col­lab­o­ra­tion between WPD Phar­ma­ceu­ti­cals and Wake For­est Uni­ver­si­ty. It is a mul­ti­va­lent tar­get­ed cyto­tox­ic drug con­ju­gate, which is engi­neered to tar­get four recep­tors con­comi­tant­ly: inter­leukin 13 recep­tor alpha 2 (IL-13RA2) and 3 ephrin recep­tors (EphA2, EphA3 and EphB2), that are over­ex­pressed in patients with glioblas­toma (GBM), the most preva­lent pri­ma­ry brain tumor of dis­mal prognosis.

The cyto­tox­ic is a drug con­ju­gate com­posed of tar­get­ing moi­eties and a micro­tubu­lar inhibitor DM1. Four tar­get­ed recep­tors are expressed in near­ly 100% of glioblas­tomas, thus, WPD-401 can tar­get glioma cells in almost all the patient pop­u­la­tion while spar­ing nor­mal brain. The poten­cy of WPD-401 in treat­ing GBM has been already val­i­dat­ed in pre­clin­i­cal mod­els includ­ing stud­ies in dogs. A phase I clin­i­cal tri­al in dogs with spon­ta­neous gliomas using a cock­tail of lig­and-bac­te­r­i­al cyto­tox­in con­ju­gates that tar­get IL-13RA2 and EphA2 recep­tors has shown great promise.

Addi­tion­al­ly, all 4 recep­tors tar­get­ed by WPD-401 are also expressed in var­i­ous oth­er sol­id tumors, includ­ing melanoma, pan­creas, TNBC, colon can­cer, kid­ney, lung or ovary.

In con­clu­sion, WPD-401 is an inno­v­a­tive, high­ly effec­tive drug can­di­date that has the poten­tial to rev­o­lu­tion­ize treat­ment for high unmet med­ical needs in glioblas­toma, TNBC and oth­er indications.

WPD Phar­ma­ceu­ti­cals is a clin­i­cal-stage biotech­nol­o­gy com­pa­ny focused on devel­op­ing nov­el ther­a­pies for oncol­o­gy with spe­cial empha­sis on brain can­cer. WPD-401 is a nov­el and potent drug can­di­date com­ing from the col­lab­o­ra­tion between WPD Phar­ma­ceu­ti­cals and Wake For­est Uni­ver­si­ty. It is a mul­ti­va­lent tar­get­ed cyto­tox­ic drug con­ju­gate, which is engi­neered to tar­get four recep­tors con­comi­tant­ly: inter­leukin 13 recep­tor alpha 2 (IL-13RA2) and 3 ephrin recep­tors (EphA2, EphA3 and EphB2), that are over­ex­pressed in patients with glioblas­toma (GBM), the most preva­lent pri­ma­ry brain tumor of dis­mal prognosis.

The cyto­tox­ic is a drug con­ju­gate com­posed of tar­get­ing moi­eties and a micro­tubu­lar inhibitor DM1. Four tar­get­ed recep­tors are expressed in near­ly 100% of glioblas­tomas, thus, WPD-401 can tar­get glioma cells in almost all the patient pop­u­la­tion while spar­ing nor­mal brain. The poten­cy of WPD-401 in treat­ing GBM has been already val­i­dat­ed in pre­clin­i­cal mod­els includ­ing stud­ies in dogs. A phase I clin­i­cal tri­al in dogs with spon­ta­neous gliomas using a cock­tail of lig­and-bac­te­r­i­al cyto­tox­in con­ju­gates that tar­get IL-13RA2 and EphA2 recep­tors has shown great promise.

Addi­tion­al­ly, all 4 recep­tors tar­get­ed by WPD-401 are also expressed in var­i­ous oth­er sol­id tumors, includ­ing melanoma, pan­creas, TNBC, colon can­cer, kid­ney, lung or ovary.

In con­clu­sion, WPD-401 is an inno­v­a­tive, high­ly effec­tive drug can­di­date that has the poten­tial to rev­o­lu­tion­ize treat­ment for high unmet med­ical needs in glioblas­toma, TNBC and oth­er indications.

Beyond Glioblastoma - WPD Pharmaceuticals
Beyond Glioblastoma - WPD Pharmaceuticals
Beyond Glioblastoma - WPD Pharmaceuticals

Marek Sipow­icz

Physi­cian with over 20 years of expe­ri­ence in lead­ing clin­i­cal tri­als across oncol­o­gy (hema­to­log­ic malig­nan­cies and sol­id tumors), neu­ropsy­chi­a­try, dia­betes, and car­dio­vas­cu­lar med­i­cine. A board-cer­ti­fied gyne­col­o­gist trained in Poland, with a post­doc­tor­al fel­low­ship com­plet­ed at the Nation­al Can­cer Insti­tute in Bethes­da, USA.

A high­ly regard­ed expert in the phar­ma­ceu­ti­cal indus­try, with a track record of ini­ti­at­ing and man­ag­ing glob­al Phase I – IV clin­i­cal tri­als, includ­ing large-scale mor­tal­i­ty stud­ies. Spent over two decades in lead­er­ship roles at Servi­er, an inter­na­tion­al phar­ma­ceu­ti­cal com­pa­ny, serv­ing as Direc­tor of Clin­i­cal Oper­a­tions in Oncol­o­gy in France and Direc­tor of Clin­i­cal Research in Australia.

More about Dr. Marek Sipow­icz.

Physi­cian with over 20 years of expe­ri­ence in lead­ing clin­i­cal tri­als across oncol­o­gy (hema­to­log­ic malig­nan­cies and sol­id tumors), neu­ropsy­chi­a­try, dia­betes, and car­dio­vas­cu­lar med­i­cine. A board-cer­ti­fied gyne­col­o­gist trained in Poland, with a post­doc­tor­al fel­low­ship com­plet­ed at the Nation­al Can­cer Insti­tute in Bethes­da, USA.

A high­ly regard­ed expert in the phar­ma­ceu­ti­cal indus­try, with a track record of ini­ti­at­ing and man­ag­ing glob­al Phase I – IV clin­i­cal tri­als, includ­ing large-scale mor­tal­i­ty stud­ies. Spent over two decades in lead­er­ship roles at Servi­er, an inter­na­tion­al phar­ma­ceu­ti­cal com­pa­ny, serv­ing as Direc­tor of Clin­i­cal Oper­a­tions in Oncol­o­gy in France and Direc­tor of Clin­i­cal Research in Australia.

More about Dr. Marek Sipow­icz.

profile
Marek Sipow­icz, WPD Phar­ma­ceu­ti­cals, POLAND

Read the Abstracts from Our Invit­ed Speakers

Can­cer Biology

Can­cer Neuroscience

Can­cer Therapy

PORT for Busi­ness — Com­pa­ny Session